Robyn Osborn

multiple myeloma coach since 2025

Hi! I was diagnosed with myeloma in June 2024, so I'm still relatively new to this myeloma game. I was diagnosed with MGUS in early 2020 and monitored for three years. By summer 2023, my MM specialist began to suspect Smoldering Myeloma, which was confirmed with a bone marrow biopsy in August 2023. At that time, he encouraged me to start MM treatment with DRVd, but I was reluctant because I had no symptoms and didn't have active MM, yet. I decided to get a second opinion, and that MM specialist recommended holding off on treatment until, and if, I developed active MM. By March 2024, I began to experience fatigue and shortness of breath, and in May 2024, a bone marrow biopsy confirmed that I now had active MM. On June 17, 2024, I started induction therapy on DRVd. About 4 cycles, my MM specialist decided I was not a good candidate for a SCT, so as a result, she had me complete 6 cycles of Induction therapy. In mid-November, I began experiencing peripheral neuropathy in my feet, which she attributed to the Velcade, so she stopped treatment. My kappa light chains and m-spike were within normal range, so she determined that I was ready to move on to maintenance. Those were the sweetest words I had heard in a while! In December 2024, I started on monthly Darzalex Faspro (Dara). Even though Revlimid is standard of care in maintenance, she decided against adding it back in due to the related side effects I had suffered during induction. So, for now, I am on maintenance with monthly Dara, with no noticeable side effects, I'm happy to add, and I also receive Zometa infusions every 3 months, which were started in July 2024. I am also happy to report that my kappa light-chains are still within normal range, and my M-Spike in April was zero!

Dorian Soper

multiple myeloma coach since 2024

I was Dx in December of 2020 with Smoldering MM, borderline stage 1, (R-ISS.) IGG Lambda ,1Q,11:14 (15%.) Pet scan, bone survey neg; no renal involvement. Started 24 month clinical trial in Feb, 2021: Dara, Revlimid and Dex. Completed study in December, 2022. I had a partial response. Presently, I am not taking any MM meds and see my oncologist every month after blood screening. My labs are "stable." I always say that I am "flying under the radar" and am very grateful to be doing so. I am the eternal optimist and strongly believe that the cure for MM is right arounds the corner. Coaching allows me to steer patients towards a the wealth of information offered by Healthtree. Knowledge is the power for the cure. Thank you, Dorian Soper

John Rosengard

multiple myeloma coach since 2021

Diagnosed November 2017. Joined GRIFFIN Phase 2/3 clinical trial (D-RVd) then stem cell transplant in May 2018. Remission in May 2018. In January 2021, finished full 32 cycles of the GRIFFIN clinical trial. For post-GRIFFIN treatment, I elected to change from Revlimid (21 capsules/month) to Daratumumab (DARZALEX FASPRO, one injection per month) in April 2021. After good FISH and cloneSEQ results in May 2023, ended the dara maintenance to watch impact on blood numbers. Patient of Dr. Nina Shah (<May 2022), then Dr. Tom Martin at UCSF. Oakland, California. Blue Shield of CA is my insurer.